Johnson & Johnson’s Janssen division (NYSE:JNJ) was among the first drug companies to prioritize oncology research.
The company has more than three decades of experience in the domain. Recently, CAR-T therapy has become “one of the most exciting areas of research for cancer and other diseases for the company, said Mathai Mammen, global head of R&D for Janssen, in a recent interview.
In the following Q&A, Mammen provides an overview of the company’s CAR-T research while also touching on its work to revise the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). He also touches on new potential indications for Nipocalimab, a fully-human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody, and dishes on the company’s investment in data science in the development of drugs and vaccines.
Drug Discovery & Development: Could you provide a brief overview of Janssen’s work on CAR-T (including ciltacabt…